Black Health
Integrase strand transfer inhibitor HIV-1 treatment

Dolutegravir (Tivicay, Dovato (with lamivudine), Triumeq (with ABC/3TC)) and Black patients

Brand names: Tivicay, Dovato (with lamivudine), Triumeq (with ABC/3TC)

Last reviewed: Sources checked:

What Dolutegravir does

Dolutegravir is an integrase inhibitor with a high barrier to resistance and excellent tolerability. It is part of first-line HIV regimens worldwide and, as a single-drug agent, partners with backbone NRTIs (TDF/FTC, ABC/3TC, 3TC alone in Dovato).

What the evidence says for Black patients

Dolutegravir has the largest cumulative Black-patient data of any ART, from WHO-recommended use across sub-Saharan Africa. Key points:

  • Virological efficacy is equivalent to or better than efavirenz, raltegravir, and darunavir/ritonavir across all studied populations (SINGLE, FLAMINGO, SAILING, ADVANCE, NAMSAL).
  • Early pregnancy signal (Tsepamo, 2018) suggested increased neural tube defects with preconception dolutegravir exposure. Follow-up analyses (Zash et al., NEJM 2021;384:827–40, PMID 33730454) reduced the estimate to ~0.11 percent absolute increase — still notable but much smaller than originally feared. WHO and DHHS now recommend dolutegravir across pregnancy with informed discussion. For Black women of childbearing age with HIV, this conversation is particularly important.
  • Dolutegravir/lamivudine (Dovato) is a 2-drug regimen with strong data in Black participants (GEMINI 1/2 and TANGO trials).
  • Weight gain with dolutegravir + TAF in Black women (ADVANCE) — noted above on the Biktarvy page — applies; TDF-containing regimens may be preferred for some patients.

Common alternatives

Bictegravir (Biktarvy) — single-tablet. Raltegravir (older INSTI). Elvitegravir/cobicistat (Stribild, Genvoya). For pregnancy: multiple options with individualized risk discussion.

Side effects

  • Headache, insomnia
  • Rare neuropsychiatric — depression, suicidal ideation
  • Weight gain (see Biktarvy)
  • Small creatinine rise
  • Rare hypersensitivity

Factors that affect adherence

Once-daily oral. Separate from antacids. Ryan White / ADAP covers in the US; WHO/PEPFAR distributes generic dolutegravir broadly in sub-Saharan Africa.

Questions to ask your doctor

Bring this list to your next appointment.

  • If I'm pregnant or might become pregnant, what's the current guidance on dolutegravir?
  • Am I on a TAF- or TDF-containing backbone, and does weight-gain risk change that choice for me?
  • What's my viral load trajectory?

References

  1. Zash R, Holmes L, Diseko M, et al. Neural-tube defects and antiretroviral treatment regimens in Botswana. NEJM. 2019;381:827–840. PMID 31339676.
  2. Zash R et al. Update on Neural Tube Defects (NTDs) with dolutegravir exposure. NEJM. 2021;384:827–840.
  3. Walmsley SL, Antela A, Clumeck N, et al. Dolutegravir plus abacavir–lamivudine for the treatment of HIV-1 infection (SINGLE). NEJM. 2013;369:1807–1818.
  4. DHHS Panel on Antiretroviral Guidelines. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV.
  5. U.S. Food and Drug Administration. Tivicay (dolutegravir) label. https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/204790lbl.pdf

Medical disclaimer

This page is patient education, not prescribing guidance. It summarizes the published evidence about how this medication has been studied in Black patients — it is not a substitute for the judgment of your personal clinician. Never start, stop, or change a prescription based on something you read here. If you have questions about your medication, call your prescriber or pharmacist. For emergencies, call 911.

Read our editorial standards for how we source, review, and update these pages.